Canagliflozin 50 mg

DRUG5 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen Research & Development, LLC

Conditions

Diabetes Mellitus, Type 2Healthy

Phase 1

A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus

CompletedNCT01128985

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Diabetes Mellitus, Type 2

Start: 2010-03-31End: 2010-07-31Updated: 2013-05-29

A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers

CompletedNCT01281579

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy

Start: 2011-01-31End: 2011-04-30Updated: 2012-11-30

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

CompletedNCT02000700

Janssen Research & Development, LLCDiabetes Mellitus, Type 2

Start: 2014-03-31End: 2016-04-30Updated: 2017-03-03

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

CompletedNCT02846506

Janssen Research & Development, LLCHealthy

Start: 2016-08-31End: 2016-10-31Updated: 2025-02-03

Phase 2

An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

CompletedNCT01340664

Janssen Research & Development, LLCDiabetes Mellitus, Type 2

Start: 2011-07-31End: 2012-04-30Updated: 2014-09-16

Related Papers

Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus.

2014-05-0527 citations